EP Patent

EP0268215A1 — Inclusion complex of ibuproxam with beta-cyclodextrin, a process for preparing the same and a pharmaceutical preparation containing the same

Assigned to Lek Pharmaceuticals dd · Expires 1988-05-25 · 38y expired

What this patent protects

A new inclusion complex of ibuproxam with beta-cyclodextrin is described, which is prepared by adding ibuproxam to a boiling aqueous solution of beta-cyclodextrin, stirring the reaction mixture at the boiling temperature, cooling to a temperature of 0° to 5°C and isolating …

USPTO Abstract

A new inclusion complex of ibuproxam with beta-cyclodextrin is described, which is prepared by adding ibuproxam to a boiling aqueous solution of beta-cyclodextrin, stirring the reaction mixture at the boiling temperature, cooling to a temperature of 0° to 5°C and isolating the title complex. The analgesic, antipyretic and antiinflammatory propeties of the inclusion complex of ibuproxam with beta-cyclodextrin are equivalent to those of ibuproxam alone, but owing to its better water-solubility the complex can be more easily formulated into pharmaceutical forms.

Drugs covered by this patent

Patent Metadata

Patent number
EP0268215A1
Jurisdiction
EP
Classification
Expires
1988-05-25
Drug substance claim
No
Drug product claim
No
Assignee
Lek Pharmaceuticals dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.